[{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"030e193e-34f1-4703-8b20-39ecf51033c3","acronym":"EPIK-O","url":"https://clinicaltrials.gov/study/NCT04729387","created_at":"2021-01-28T12:53:14.669Z","updated_at":"2025-02-25T15:19:01.385Z","phase":"Phase 3","brief_title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","source_id_and_acronym":"NCT04729387 - EPIK-O","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Piqray (alpelisib) • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 04/21/2023","primary_completion_date":" 04/21/2023","study_txt":" Completion: 06/04/2025","study_completion_date":" 06/04/2025","last_update_posted":"2025-02-12"},{"id":"45f2fe3c-e709-4312-adf3-701774e498ee","acronym":"ATALANTE","url":"https://clinicaltrials.gov/study/NCT02891824","created_at":"2021-01-18T14:11:40.169Z","updated_at":"2025-02-25T15:33:43.991Z","phase":"Phase 3","brief_title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","source_id_and_acronym":"NCT02891824 - ATALANTE","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 614","initiation":"Initiation: 09/22/2016","start_date":" 09/22/2016","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 02/22/2024","study_completion_date":" 02/22/2024","last_update_posted":"2025-02-11"},{"id":"424f1715-a08a-4e86-a255-1bc30e3c69e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203525","created_at":"2021-01-18T15:47:47.088Z","updated_at":"2025-02-25T15:42:56.837Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","source_id_and_acronym":"NCT03203525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"6a7e2afb-013b-43d3-b31e-6052a197be35","acronym":"met-HEReMYTA","url":"https://clinicaltrials.gov/study/NCT02488564","created_at":"2021-01-18T11:59:22.933Z","updated_at":"2025-02-25T16:58:50.319Z","phase":"Phase 2","brief_title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02488564 - met-HEReMYTA","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • metformin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/17/2014","start_date":" 12/17/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2025-02-03"},{"id":"caa0f388-4c19-438d-9bce-36b37f87c82f","acronym":"NRG-GY004","url":"https://clinicaltrials.gov/study/NCT02446600","created_at":"2021-01-18T11:43:37.532Z","updated_at":"2025-02-25T15:06:35.061Z","phase":"Phase 3","brief_title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02446600 - NRG-GY004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 579","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 02/23/2020","primary_completion_date":" 02/23/2020","study_txt":" Completion: 08/23/2025","study_completion_date":" 08/23/2025","last_update_posted":"2025-02-03"},{"id":"fcfcabed-9306-4c49-86eb-f669bd54b895","acronym":"ICON","url":"https://clinicaltrials.gov/study/NCT03409198","created_at":"2021-01-18T16:49:12.658Z","updated_at":"2025-02-25T14:37:58.313Z","phase":"Phase 2","brief_title":"Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer","source_id_and_acronym":"NCT03409198 - ICON","lead_sponsor":"Oslo University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 01/21/2018","start_date":" 01/21/2018","primary_txt":" Primary completion: 05/11/2022","primary_completion_date":" 05/11/2022","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2024-10-14"},{"id":"da15b8b1-2121-407f-8c22-f4a9fa579eab","acronym":"ANITA","url":"https://clinicaltrials.gov/study/NCT03598270","created_at":"2021-01-18T17:41:31.483Z","updated_at":"2025-02-25T13:18:34.592Z","phase":"Phase 3","brief_title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03598270 - ANITA","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","biomarkers":" TMB • BRCA","pipe":" | ","alterations":" PD-L1 expression • BRCA mutation","tags":["TMB • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • gemcitabine • paclitaxel • Zejula (niraparib) • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 417","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 08/05/2024","primary_completion_date":" 08/05/2024","study_txt":" Completion: 08/05/2024","study_completion_date":" 08/05/2024","last_update_posted":"2024-08-30"},{"id":"b4084e04-80e0-4936-af0c-62552e92f11e","acronym":"DETECT III","url":"https://clinicaltrials.gov/study/NCT01619111","created_at":"2021-01-18T06:56:21.591Z","updated_at":"2024-07-02T16:34:58.993Z","phase":"Phase 3","brief_title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","source_id_and_acronym":"NCT01619111 - DETECT III","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • lapatinib • capecitabine • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2024-06-04"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"4c69c646-417d-429d-bb95-ea9731d61b06","acronym":"COCOS","url":"https://clinicaltrials.gov/study/NCT02502266","created_at":"2021-01-18T12:04:33.243Z","updated_at":"2024-07-02T16:35:02.420Z","phase":"Phase 2/3","brief_title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02502266 - COCOS","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 562","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-21"},{"id":"a0e00cfa-2eb4-4439-8a06-39293232dc5b","acronym":"Actuate 1801","url":"https://clinicaltrials.gov/study/NCT03678883","created_at":"2021-01-18T18:02:27.392Z","updated_at":"2024-07-02T16:35:15.452Z","phase":"Phase 2","brief_title":"9-ING-41 in Patients With Advanced Cancers","source_id_and_acronym":"NCT03678883 - Actuate 1801","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-11"},{"id":"8e2f554f-5b71-4b80-85eb-7d4289eed34a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456857","created_at":"2021-01-18T11:47:13.758Z","updated_at":"2024-07-02T16:35:19.566Z","phase":"Phase 2","brief_title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","source_id_and_acronym":"NCT02456857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • VIM","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-02-13"},{"id":"a012529c-d433-4cc1-950b-b069e61ba45c","acronym":"MIROVA","url":"https://clinicaltrials.gov/study/NCT04274426","created_at":"2021-01-18T20:45:40.588Z","updated_at":"2024-07-02T16:35:23.352Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04274426 - MIROVA","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA1 • BRCA2 • FOLR1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-15"},{"id":"0b6d7e60-5588-4d27-b84f-436660d0c1bd","acronym":"NRG-GY009","url":"https://clinicaltrials.gov/study/NCT02839707","created_at":"2021-01-18T13:56:21.115Z","updated_at":"2024-07-02T16:35:29.911Z","phase":"Phase 2/3","brief_title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02839707 - NRG-GY009","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 443","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 05/09/2023","primary_completion_date":" 05/09/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"41bdcc77-e116-46fe-a0f3-0a261fd36d4e","acronym":"ALICE","url":"https://clinicaltrials.gov/study/NCT03164993","created_at":"2021-01-18T15:36:16.919Z","updated_at":"2024-07-02T16:35:30.758Z","phase":"Phase 2","brief_title":"Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT03164993 - ALICE","lead_sponsor":"Oslo University Hospital","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cyclophosphamide • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 04/25/2023","primary_completion_date":" 04/25/2023","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-11-01"},{"id":"7d38238f-0360-4cbf-a047-99f5bdad7662","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272790","created_at":"2021-01-18T10:41:27.352Z","updated_at":"2024-07-02T16:35:34.901Z","phase":"Phase 2","brief_title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02272790","lead_sponsor":"AstraZeneca","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • adavosertib (AZD1775) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/30/2015","start_date":" 01/30/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2023-10-03"},{"id":"256f6a8e-3640-4144-95e9-fbf5740986e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03712956","created_at":"2021-01-18T18:12:04.103Z","updated_at":"2024-07-02T16:35:36.349Z","phase":"Phase 2","brief_title":"CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER","source_id_and_acronym":"NCT03712956","lead_sponsor":"European Institute of Oncology","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 03/25/2016","start_date":" 03/25/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-09-21"},{"id":"d68c21bc-30b1-4db8-a332-083cde839ded","acronym":"CARABELA","url":"https://clinicaltrials.gov/study/NCT04293393","created_at":"2021-01-18T20:49:58.372Z","updated_at":"2024-07-02T16:35:42.612Z","phase":"Phase 2","brief_title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","source_id_and_acronym":"NCT04293393 - CARABELA","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • Verzenio (abemaciclib) • cyclophosphamide • letrozole • pegylated liposomal doxorubicin • goserelin acetate • leuprolide acetate for depot suspension • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 06/21/2023","primary_completion_date":" 06/21/2023","study_txt":" Completion: 02/28/2033","study_completion_date":" 02/28/2033","last_update_posted":"2023-07-19"},{"id":"f2ecb7df-f00d-44ff-87c8-7ca1763ca133","acronym":"JAVELIN Ovarian 200","url":"https://clinicaltrials.gov/study/NCT02580058","created_at":"2021-01-18T12:30:43.015Z","updated_at":"2024-07-02T16:35:43.530Z","phase":"Phase 3","brief_title":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)","source_id_and_acronym":"NCT02580058 - JAVELIN Ovarian 200","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • CD8 positive","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 566","initiation":"Initiation: 12/21/2015","start_date":" 12/21/2015","primary_txt":" Primary completion: 09/19/2018","primary_completion_date":" 09/19/2018","study_txt":" Completion: 07/12/2022","study_completion_date":" 07/12/2022","last_update_posted":"2023-07-10"},{"id":"ddbbe2bc-35d5-410d-a135-625e3b0c3a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT02315196","created_at":"2021-01-18T10:58:05.394Z","updated_at":"2024-07-02T16:35:51.960Z","phase":"Phase 2","brief_title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","source_id_and_acronym":"NCT02315196","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" HER-2 • PGR • CASP3","pipe":" | ","alterations":" TP53 mutation • HER-2 negative","tags":["HER-2 • PGR • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pegylated liposomal doxorubicin • epirubicin • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 02/25/2015","start_date":" 02/25/2015","primary_txt":" Primary completion: 02/08/2021","primary_completion_date":" 02/08/2021","study_txt":" Completion: 07/01/2041","study_completion_date":" 07/01/2041","last_update_posted":"2023-03-29"}]